Biopharmaceutical Logistics Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025– 2034
Report ID: GMI4188
Download Free PDF
Authors:
Mariam Faizullabhoy ,
Biopharmaceutical Logistics Market Size
The global biopharmaceutical logistics market size generated notable revenues in 2024 and is predicted to grow at a substantial CAGR between 2025-2034 driven by the heightened demand for temperature-sensitive biologics, vaccines, cell and gene therapies, and specialty products. According to the WHO, in 2023, there were 88 types of vaccine products distributed to 207 countries and procurement channels from 116 vaccine manufacturers.
The continuing growth of biopharmaceuticals requires compliance with highly regulated storage and transportation environments, making the specialized biopharmaceutical logistics sector a key component in the pharmaceutical supply chain. In addition, the steady growth of global healthcare spending, and clinical trials, as well as personalized medicine have resulted in more complex, and geographically disparate supply chain solutions requiring more dependable logistics requirements.
Biopharmaceutical logistics plays an important role in delivering biologics and other temperature-sensitive medications to the healthcare provider or patient safely and efficiently. Organizations such as the FDA, EMA, and the WHO impose strict regulations on principles of preservation including supply chain quality control, and disbursement of approved products. End users require greater reliability, therefore, environmental controls throughout the entire supply chain must be complete from manufacturing sites down to end users.
Furthermore, the pandemic spurred an unprecedented demand for reliable cold chain logistics, and global attention was raised about safe transport and storage of temperature-sensitive drugs. Complying with diverse regulatory standards across countries involves extensive documentation, validation, and auditing processes, which can slow down logistics operations and increase costs hindered the market growth.
Biopharmaceutical Logistics Market Trends
The biopharmaceutical logistics market is changing quickly and there are numerous trends shaping the evolution of how drugs are stored and distributed around the world. One of the primary trends is the use of real-time technology-based logistics tools such as standards for shipment tracking, predictive analytics, and temperature monitoring of shipments by Internet of Things (IoT) connected devices. These logistics tools are improving supply chain visibility and allowing for speedier responses to trouble that arises months later in the supply chain while improving regulatory compliance. Some blockchain technology is also being investigated for end-to-end traceability, security improvements, and addressing counterfeit pharmaceuticals.
Sustainability is another prime trend. Environmental sustainability has a greater emphasis on logistics organizations changing to the use of sustainable materials, their packaging, their transit routes, and their fleets to decrease carbon emissions, including electric or hybrid methods. There is a growing interest in managed cloud platforms for logistics which provides better centralization of control and coordination of complex supply chains. Additionally, logistics providers are evolving to provide tailored, versatile, and immediate logistics options for customizable solutions that meet individualized patient and regulatory requirements, especially for growing personalized therapies and direct-to-patient delivery.
Lastly, global disruptions from pandemic pressures and geographic instability have illustrated the need for resilient and flexible logistics networks. Companies are re-examining their supply chain strategies to factor in health and social responsibilities while incorporating a multi-sourcing supply approach.
Biopharmaceutical Logistics Market Analysis
The Cold chain logistics segment in the biopharmaceutical logistics market accounted for a large share in 2024. Cold chain logistics includes the transportation and storage of pharmaceutical products, such as vaccines, biologics, and cell and gene therapies, that are temperature sensitive. They must be transported in a tightened range of temperatures to remain effective and safe to use. Cold chain logistics is when temperature-controlled trucks, containers, cold rooms, data loggers, and digital monitoring systems maintain the same environmental conditions across the distribution period.
The rising demand for mRNA-based vaccines and gene therapies has underscored the need for advanced cold chain infrastructure due to their ultra-cold or cryogenic requirements (meaning they need to be shipped and stored between -80 and -196 C). Phase change material, vacuum-insulated panels, and real-time temperature monitoring devices have also made cold chain operations more reliable and secure. Also, companies are investing money into more elaborate packaging of products and expanding their cold chain because of increased volume.
The warehousing and storage segment in the biopharmaceutical logistics market held a substantial share in 2024, as they provide storage for sensitive products, compliant, and temperature-controlled suitable for storing products until distribution. As there is a complexity of biopharmaceutical supply chains, along with a continuing requirement for regional distribution centers the market is expected to grow. Biopharmaceuticals are required to be stored anywhere from ambient through cryogenic temperatures, which is proliferating logistics providers to create increasingly varying and specialized warehousing facilities.
This means having facilities with cold rooms, humidity control, backup power, and real-time inventory management. The growing usage of personalized medicine and cell-based therapies is also leading to the demand for warehouses to facilitate greater flexibility and responsiveness for storage and distribution. Warehouses are now considered warehouse/distribution centers or operational distribution centers, where the warehouse can label, repackage, and kit according to what the patient needs.
Asia Pacific biopharmaceutical logistics market generated notable revenues in 2024 and is expected to continue growing steadily through 2034 due to a large increase in pharmaceutical manufacturing, increases in healthcare investments, and a continued increase in demand for biologic and specialty drugs in countries like China, India, Japan, South Korea, and Australia. Government policies and programs that further enhance medicines' production capabilities, government support for funding biotechnology-related research and innovations, and investments in cold-chain infrastructure, are establishing Asia Pacific as a key player in the biopharmaceutical logistics industry and the global pharmaceutical supply chain.
As a result of increased demand for pharmaceutical logistics services, we have seen international logistics companies expanding in Asia Pacific, forming strategic partnerships, and investing in larger facilities. Increased demand for clinical trials in the Asia Pacific region has also contributed to the need for logistics solutions that can manage sourcing and administrative challenges, particularly from the perspective of sample collection, storage, and distribution. In addition, increased middle-class income and healthcare access have led to an increase in demand for more advanced therapeutics, which may include biosimilars and vaccines that require temperature-controlled logistics.
Biopharmaceutical Logistics Market Share
Some major companies in the biopharmaceutical logistics industry include:
Organizations engaged in biopharmaceutical logistics market are making a variety of strategic investments in buildings, technology, funding, and partnerships to strengthen their competitive position. Logistics companies in biopharmaceutical logistics are investing in the development of cold chain markets around temperature-controlled warehouses and regional distribution facilities. The integration of IoT, AI, and blockchain for traceability, compliance, and real-time monitoring is also taking place. Logistics companies are building partnerships with pharmaceutical companies and public health and government organizations to form longer-term contracts and access new market opportunities. Logistics companies are developing capabilities for last-mile delivery with advanced medical deliveries related to personalized or direct-to-patient services.
Biopharmaceutical Logistics Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →